查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835365

体外诊断品管市场（按产品类型、技术、应用和最终用户）—全球预测 2025-2032

In-Vitro Diagnostics Quality Control Market by Product Type, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年体外诊断品管市场将成长至 28.8 亿美元，复合年增长率为 8.62%。

主要市场统计数据
预测年份（2024年） 14.8亿美元
基准年（2025年） 16.1亿美元
预测年份（2032年） 28.8亿美元
复合年增长率（%） 8.62%

在技​​术融合、监管审查和操作复杂性的背景下，品管已成为临床实验室的基本必需品。

引言将体外诊断品管定位为现代临床实验室运作的支柱，对病人安全、法规遵循和临床决策的可靠性至关重要。分析平台的进步、复杂分子检测的普及以及诊断在个人化医疗中日益重要的作用，大大提升了稳健品管系统的重要性。随着实验室和製造商寻求仪器、试剂和数据系统的统一性能，能够证明一致的精密度和准确度变得前所未有的重要。

本节将当前发展置于技术融合和监管审查日益严格的大背景下。它强调了仪器、品管材料和软体在建构闭合迴路品管生态系统过程中的相互作用。它还强调了实验室负责人和製造商如何适应日益严格的可追溯性要求以及对整合资料管理的期望。随后，叙述转向认识该行业面临的营运挑战，包括劳动力技能差距、供应链复杂性以及对标准化绩效指标的需求，为后续更详细的分析奠定基础。

技术、数位和监管的快速变化如何重塑诊断品管实践和供应商与实验室的合作

技术创新、数位化和监管变革的交汇正在加速体外诊断品管领域的变革。新的仪器平台实现了更高的通量和自动化程度，因此需要更复杂的品管材料和试剂配方来检验更广泛的动态范围。随着硬体的进步，资料管理和品质保证的软体解决方案也日趋成熟，实现了即时监控和预测分析，从而彻底改变了实验室处理过程控制和偏差管理的方式。

同时，分子诊断和免疫检测的兴起，以及即时检测的普及，使得确保不同环境下结果完整性所需的控制类型变得多样化。这种多样化迫使製造商和实验室重新思考互换性、校准策略和跨平台等效性。监管机构正在製定更详细的验证和上市后监管指南，敦促相关人员将监管资讯整合到产品开发生命週期中。这些共同的转变正在重塑采购重点、供应商关係以及实验室员工所需的技能，推动朝向更具协作性、技术支援的品质生态系统迈进。

评估2025年美国关税改革如何影响诊断品管供应链弹性、筹资策略和业务连续性

美国实施的2025年新关税对与体外诊断品管相关的供应链、筹资策略和产品成本结构产生了实际的连锁反应。依赖跨境製造和零件采购的分析仪器、品管材料、试剂和专用软体供应商正在调整其物流和定价模式，以缓解利润压力并维持可靠的交货时间。为此，采购组织和实验室管理人员正在重新考虑供应商多元化和库存策略，以保持关键品管材料和试剂的连续性。

在营运方面，一些製造商正在加快本地化生产流程、重新设计包装以提高成本效益，并重新配置采购以最大限度地降低关税的影响。虽然这些措施提高了韧性，但随着新生产线和替代供应商的检验，它们也可能导致前置作业时间和资格要求的变化。重点，关税凸显了透明供应商资料和可追溯性的价值，强化了严格的批次间检验程序和全面文件的必要性。总而言之，这些发展促使人们重新审视整体拥有成本和风险管理方法，相关人员优先考虑策略伙伴关係和供应链可视性，以维持不间断的品管营运。

全面的细分洞察将产品类型、技术应用和最终用户动态与业务优先事项和供应商策略联繫起来

细分驱动的洞察揭示了每种产品、技术、应用和最终用户类别的细微价值提案和业务需求，每种类别都需要针对供应商和实验室制定量身定制的策略。根据产品类型，分析仪和仪器需要专注于系统互通性和维护工作流程；自动化系统有助于提高通量，而半自动化系统则具有灵活性和小批量部署能力；质控品必须满足稳定性和基质匹配的要求；液体质控品提供即用型便利，而冻干质控品则可延长保质期。

从技术角度来看，临床化学检测涵盖比色法和浊度法，对试剂呈现和校准有不同的要求；免疫检测包括化学冷光、ELISA 和萤光形式，每种方法都需要客製化的校准器和干扰测试。微生物学工作流程区分基于培养的方法和 PCR 技术，具有不同的控制需求。特定应用细分强调了循环系统检测如何优先考虑心臟标记的稳定性和照护现场的稳健性；基因检测如何影响携带者和产前检测的准确性；传染病检查如何需要细菌和病毒检测验证；肿瘤学如何优先考虑微小残留病和肿瘤标记的保真度；以及毒理学如何平衡滥用药物筛检和治疗药物监测的准确性。最终用户细分说明了血库、诊断实验室、医院和诊所以及研究机构之间不同的运作重点。国家与地区血库营运影响规模和库存管理；医院实验室与独立实验室有不同的认证和工作流程整合需求；诊所级与参考实验室服务有不同的测试广度和周转预期；学术研究机构和商业研究机构在出版和转化计划的探索性检测开发和严格控制验证之间取得了不同的平衡。

综合起来，这些细分见解表明，供应商应优先考虑模组化产品系列、经过验证的跨平台相容性和灵活的检验检验和整合数据策略，以管理复杂性并确保一致的诊断性能。

美洲、欧洲、中东和非洲地区以及亚太地区采购、检验和采用品管解决方案的区域动态和实际意义

区域动态正在影响品管解决方案的采购决策、监管方法和采用路径，每个地区都呈现不同的驱动因素和限制因素。美洲地区专注于整合实验室网络，并投资于自动化和数位化品质工具，以满足快速週转和监管可追溯性的期望。相较之下，欧洲、中东和非洲地区的管理体制制度和基础设施成熟度参差不齐，既有采用高度复杂管理系统的集中式标准实验室，也有优先考虑经济高效、稳健的管理系统和适用于分散环境的可携式解决方案的小型设施。

同时，亚太地区的特点是快速采用新型诊断技术，对实验室现代化进行大量投资，并拥有多元化的供应商，包括全球性和区域性製造商。虽然区域趋势在互通性、资料标准化和供应链弹性方面趋于一致，但实施时间表和资源配置却存在显着差异。因此，国际供应商和实验室网路必须根据区域法规结构、采购週期和基础设施能力来客製化其上市方案和验证方案，以实现整个区域有效且永续的品管整合。

主要企业如何整合产品系列组合、服务产品和策略伙伴关係关係，重新定义品管竞争力

体外诊断品管领域的主要企业在创新、策略伙伴关係和差异化服务之间寻求平衡，以确保长期的客户关係。市场领导者强调整合产品，将校准控制、相容试剂和云端软体结合，以提供无缝的检验工作流程和可审核的报告。与仪器製造商和临床实验室建立策略联盟的情况很常见，这使得能够共同开发能够满足特定平台性能特征并加速实验室采用的控制方案。

同时，一些公司正在投资提高製造严谨性和供应链透明度，以满足日益增长的监管要求，这些要求包括可追溯性和批次级文件记录。以服务主导的差异化，例如客製化验证支援、远端监控和嵌入式培训计划，正在成为减少实施摩擦和加强客户维繫的关键增值服务。此外，专注于分子诊断控制和照护现场相容性等细分领域的规模较小、专业化的公司正在应对日益复杂的检测方法和尚未满足的验证需求。总而言之，这些方法正在重塑竞争动态，成功与否越来越取决于能否提供端到端解决方案，使技术性能与实际实验室工作流程和监管期望相一致。

优先采取实际行动，增强供应链弹性、互通性、劳动力能力以及永续诊断品管的验证支持

针对行业领导者的可行建议主要集中在增强供应链韧性、提高互通性以及投资员工能力以维持高品质的诊断产出。製造商应优先考虑模组化设计和跨平台检验，以减少相容性障碍并简化实验室的采购决策。此外，提高批次可追溯性和生产绩效的透明度将有助于满足监管优先事项并增强临床客户信心。这些措施应辅以可扩展的服务模式，包括验证协助、培训和远端监控，以加快实验室团队的能力提升。

实验室和卫生系统应正式製定包含可靠文件的控制检验通讯协定，并利用先进的资料管理系统来检测细微的效能变化。采购机构应实现供应商关係多元化，并在合约中纳入应急计划，以最大程度地减少地缘政治或关税相关衝击造成的中断。对劳动力发展的投资，尤其是在资讯科学、检测验证和品质保证方面的投资，对于实现自动化和数位化品质工具的优势至关重要。总而言之，这些建议旨在协调技术、营运和商业性优先事项，以确保在不同检测环境中获得准确、可靠且合规的诊断结果。

采用严格的混合方法，结合访谈特定的规范分析和三角测量证据，以确保品管的实用性和技术相关性。

调查方法结合了主要定性输入、二手文献综述以及技术和监管资讯的结构化整合，以对品管动态进行全面评估。主要输入包括实验室主任、品管和产品负责人的访谈，并辅以与监管专家的咨询，以了解营运痛点、验证实践和采购考量，并解读指导和执法趋势。二级资讯来源包括同行评审文献、标准文件和公开的监管信息，这些信息为控制设计和验证提供了技术基础。

我们的分析方法结合了访谈资料的主题编码、与已记录标准的交叉检验以及比较案例分析，以揭示提供者方法、实验室工作流程和区域采用情况的模式。我们对多个证据流的发现进行了三角测量，以确保我们的结论既反映了实践经验，也反映了已记录的要求。我们也承认专有数据或新技术阻碍了全面可视化的局限性，并建议了可随着新证据的出现而改进的适应性策略。总体而言，我们的方法旨在为参与诊断品管的相关人员在技术严谨性和实践相关性之间取得平衡。

总结为什么互通性和供应链透明度的劳动力投资将决定诊断品管的信任和合规性的未来

总而言之，维持和提高体外诊断的品质是维护临床信心和合规性的策略要务。该行业正经历快速变革，这得益于技术创新、对分子和免疫检测的日益依赖，以及对数据可追溯性和供应链透明度日益增长的期望。这些因素既带来了挑战，也带来了机会：挑战在于协调跨平台性能并确保供应链的弹性；机会在于利用数位化工具、模组化控制产品和合作伙伴关係关係来简化验证和监控。

展望未来，那些拥抱互通性、投资于员工队伍并采用积极主动的供应链和验证策略的相关人员将最有能力确保诊断绩效的一致性，并有效应对不断变化的监管要求。本文提出的整合提供了一个框架，用于确定行动的优先顺序和资源的协调，以帮助实验室和製造商在复杂且快速发展的环境中提供可靠的、以患者为中心的诊断结果。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 引入人工智慧驱动的影像分析，用于血液检测的自动化品管
  • 区块链的引入将实现诊断中试剂批次管理的可追溯性。
  • 开发具有整合设备品管指标的照护现场检测
  • 新兴市场快速抗原检测品质标准的监管协调
  • 使用数位双胞胎模拟预测自动免疫检测平台的系统故障
  • 集中临床实验室多检体物能力验证通讯协定的标准化
  • 整合物联网感测器，用于在分析前即时监控样品处理状况
  • 冻干控製材料的进展，可延长远距离诊断环境中的稳定性

第六章：美国关税的累积影响（2025年）

第七章：人工智慧（AI）的累积影响（2025年）

第八章体外诊断品管市场（依产品类型）

  • 分析和测量设备
    • 全自动系统
    • 半自动系统
  • 控製材料
  • 品管（QC）试剂
    • 流体控制
    • 冷冻干燥控制
  • 软体解决方案
    • 资料管理系统
    • 利莫斯
    • 品质控制软体

9. 体外诊断品管市场（依技术）

  • 临床化学
    • 比色分析
    • 浊度计
  • 血液学
    • 自动细胞计数器
    • 流式细胞技术
  • 免疫检测
    • 化学冷光免疫检测
    • ELISA
    • 萤光免疫分析法
  • 微生物学
    • 文化
    • PCR
  • 分子诊断
    • 次世代定序
    • PCR

第 10 章体外诊断品管市场（按应用）

  • 心臟病
    • 心臟标记检测
    • 就地检验
  • 基因检测
    • 携带者筛检
    • 产前检查
  • 传染病检查
    • 细菌检测
    • 病毒检测
  • 瘤
    • 微量残存疾病
    • 肿瘤标记检测
  • 有毒物质
    • 滥用药物
    • 治疗药物监测

第11章体外诊断品管市场（依最终用户）

  • 血库
    • 国家血库
    • 社区血库
  • 诊断实验室
    • 医院附设检测室
    • 独立测试实验室
  • 医院和诊所
    • 临床实验室
    • 参考实验室
  • 研究所
    • 学术机构
    • 私人研究机构

第十二章体外诊断品管市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章体外诊断品管市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章体外诊断品管市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 市占率分析（2024年）
  • FPNV定位矩阵（2024年）
  • 竞争分析
    • Bio-Rad Laboratories, Inc.
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Roche Diagnostics International AG
    • Danaher Corporation
    • Sysmex Corporation
    • Siemens Healthineers AG
    • Ortho Clinical Diagnostics, Inc.
    • Randox Laboratories Ltd
    • BioMerieux SA
Product Code: MRR-43127F7279E1

The In-Vitro Diagnostics Quality Control Market is projected to grow by USD 2.88 billion at a CAGR of 8.62% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.48 billion
Estimated Year [2025] USD 1.61 billion
Forecast Year [2032] USD 2.88 billion
CAGR (%) 8.62%

Positioning quality control as a foundational necessity in clinical laboratories amid technological convergence regulatory scrutiny and operational complexity

The introduction frames in-vitro diagnostics quality control as an indispensable pillar of modern clinical laboratory operations, integral to patient safety, regulatory compliance, and the reliability of clinical decision-making. Advances in analytical platforms, the proliferation of complex molecular assays, and the expanding role of diagnostics in personalized medicine have collectively elevated the importance of robust quality control regimes. As laboratories and manufacturers seek to harmonize performance across instruments, reagents, and data systems, the ability to demonstrate consistent accuracy and precision has never been more critical.

This section situates current developments within a broader context of technological convergence and heightened regulatory scrutiny. It highlights the interplay between instrumentation, control materials, and software in creating closed-loop quality management ecosystems. Moreover, it underscores how laboratory leaders and manufacturers are adapting to tighter traceability requirements and expectations for integrated data management. The narrative transitions to a recognition of the sector's operational challenges, including workforce skills gaps, supply chain complexity, and the need for standardized performance metrics, setting the stage for the more detailed analyses that follow.

How rapid technological, digital, and regulatory shifts are reshaping quality control practices and vendor-laboratory collaboration in diagnostics

Transformative shifts in the in-vitro diagnostics quality control landscape are accelerating as innovation, digitalization, and regulatory evolution intersect. Emerging instrumentation platforms are delivering higher throughput and greater automation, which in turn demand more sophisticated control materials and reagent formulations to validate expanded dynamic ranges. Parallel to hardware advancement, software solutions for data management and quality assurance are maturing, enabling real-time monitoring and predictive analytics that change how laboratories approach process control and deviation management.

At the same time, the ascendancy of molecular diagnostics and immunoassays, accompanied by the proliferation of point-of-care testing, has diversified the types of controls needed to assure result integrity across settings. This diversification compels manufacturers and laboratories to rethink compatibility, calibration strategies, and cross-platform equivalence. Regulatory authorities are responding with more detailed guidance on validation and post-market surveillance, prompting stakeholders to integrate regulatory intelligence into product development lifecycles. Together, these shifts are reshaping procurement priorities, vendor relationships, and the skills required of laboratory personnel, driving a transition toward more collaborative and technology-enabled quality ecosystems.

Evaluating how 2025 United States tariff changes have influenced supply chain resilience, procurement strategy, and operational continuity for diagnostics quality control

The introduction of new tariffs in the United States during 2025 has introduced tangible ripple effects across supply chains, procurement strategies, and product cost structures relevant to quality control in in-vitro diagnostics. Suppliers of analyzers, control materials, reagents, and specialized software that rely on cross-border manufacturing and component sourcing are adjusting logistics and pricing models to mitigate margin pressure and maintain delivery reliability. In response, purchasing organizations and laboratory managers are reassessing supplier diversification and inventory strategies to preserve continuity of critical control materials and reagents.

Operationally, some manufacturers are accelerating efforts to localize production steps, redesign packaging for cost-efficiency, and reconfigure sourcing to minimize tariff exposure. These actions can improve resilience but may also introduce variability in lead times and qualification requirements as new production lines or alternative suppliers are validated. Importantly, the tariffs have underscored the value of transparent supplier data and traceability, reinforcing the need for rigorous lot-to-lot verification programs and comprehensive documentation. Collectively, these developments are prompting a reexamination of total cost of ownership and risk management practices, with stakeholders prioritizing strategic partnerships and supply chain visibility to maintain uninterrupted quality control operations.

Comprehensive segmentation insights tying product types technologies applications and end-user dynamics to operational priorities and supplier strategies

Segmentation-driven insights reveal nuanced value propositions and operational imperatives across product, technology, application, and end-user categories, each demanding tailored strategies from suppliers and laboratories. Based on product type, analyzers and instruments require attention to system interoperability and maintenance workflows, where automated systems drive throughput while semi-automated systems offer flexible, lower-volume deployment; control materials must satisfy stability and matrix-matching expectations, with liquid controls providing ready-to-use convenience and lyophilized controls offering extended shelf life; QC reagents call for validated performance across platforms; and software solutions spanning data management systems, laboratory information management systems, and dedicated QC software are increasingly central to harmonizing results and enabling audit-ready traceability.

From a technology perspective, clinical chemistry assays span colorimetric and turbidimetric modalities that place distinct demands on reagent presentation and calibration; hematology follows a split between automated cell counters and flow cytometry, influencing control complexity and verification protocols; immunoassays encompass chemiluminescence, ELISA, and fluorescence formats, each requiring tailored calibrators and interference testing; microbiology workflows differentiate between culture-based approaches and PCR techniques with divergent control needs; and molecular diagnostics-covering next-generation sequencing and PCR-necessitate highly specific controls to validate sensitivity, specificity, and library preparation steps. Application-focused segmentation highlights how cardiology testing emphasizes cardiac marker stability and point-of-care robustness, genetic testing hinges on carrier and prenatal assay accuracy, infectious disease testing requires bacterial and viral detection validation, oncology depends on minimal residual disease and tumor marker fidelity, and toxicology balances drugs of abuse screening with therapeutic drug monitoring precision. End-user segmentation illustrates divergent operational priorities across blood banks, diagnostic laboratories, hospitals and clinics, and research institutes, where national versus regional blood bank operations influence scale and inventory management, hospital-based versus independent laboratories differ in accreditation and workflow integration needs, clinic-level versus reference laboratory services vary in test breadth and turnaround expectations, and academic versus private research institutes balance exploratory assay development with rigorous control validation for publication and translational projects.

Taken together, these segmentation insights suggest that suppliers should prioritize modular product portfolios, validated cross-platform compatibility, and flexible service models, while laboratories should emphasize standardized verification protocols and integrated data strategies to manage complexity and ensure consistent diagnostic performance.

Regional dynamics and practical implications for procurement, validation, and adoption of quality control solutions across the Americas, EMEA, and Asia-Pacific

Regional dynamics shape procurement decisions, regulatory approaches, and adoption pathways for quality control solutions, with each geography presenting distinct drivers and constraints. The Americas exhibit a strong emphasis on consolidation of testing networks and investments in automation and digital quality tools to meet expectations for rapid turnaround and regulatory traceability. In contrast, Europe, the Middle East & Africa present a mosaic of regulatory regimes and infrastructure maturity, leading to a heterogeneous mix of centralized reference laboratories adopting high-complexity control systems and smaller facilities prioritizing cost-effective, robust controls and portable solutions for decentralized settings.

Meanwhile, the Asia-Pacific region is characterized by rapid adoption of novel diagnostic technologies, substantial investments in laboratory modernization, and a diverse supplier landscape that includes both global manufacturers and regionally specialized producers. Cross-regional trends are converging around interoperability, data standardization, and supply chain resilience, but implementation timelines and resource allocation differ substantially. Therefore, international suppliers and laboratory networks must tailor go-to-market approaches and validation packages to accommodate local regulatory frameworks, procurement cycles, and infrastructure capabilities to achieve effective and sustainable quality control integration across regions.

How leading companies are aligning integrated product portfolios service offerings and strategic partnerships to redefine quality control competitiveness

Leading companies in the in-vitro diagnostics quality control space are navigating a balance between technological innovation, strategic partnerships, and service differentiation to secure long-term customer relationships. Market leaders emphasize integrated offerings that combine calibrated control materials, compatible reagents, and cloud-enabled software to deliver seamless verification workflows and audit-ready reporting. Strategic collaborations with instrument manufacturers and clinical laboratories are common, enabling co-development of controls that address platform-specific performance characteristics and accelerate laboratory adoption.

In parallel, several firms are investing in enhanced manufacturing rigor and supply chain transparency to meet the increasing regulatory focus on traceability and lot-level documentation. Service-driven differentiation, such as tailored validation support, remote monitoring, and embedded training programs, is emerging as a critical value-add that reduces adoption friction and strengthens customer retention. Furthermore, smaller specialized players are focusing on niche segments-such as molecular diagnostics controls or point-of-care compatibility-to capitalize on growing assay complexity and unmet validation needs. Collectively, these approaches are reshaping competitive dynamics, with success increasingly tied to the ability to offer end-to-end solutions that align technical performance with practical laboratory workflows and regulatory expectations.

Practical prioritized actions to enhance supply chain resilience interoperability workforce capability and validation support for sustainable diagnostic quality control

Actionable recommendations for industry leaders center on strengthening supply chain resilience, enhancing interoperability, and investing in workforce capabilities to sustain high-quality diagnostics outputs. Manufacturers should prioritize modular design and cross-platform validation to reduce compatibility barriers and simplify procurement decisions for laboratories. In addition, increasing transparency around lot traceability and manufacturing provenance will address regulatory priorities and build trust among clinical customers. These measures should be complemented by scalable service models that include validation support, training, and remote monitoring to reduce time-to-competence for laboratory teams.

Laboratories and health systems should formalize control verification protocols that incorporate robust documentation and leverage advanced data management systems to detect subtle performance shifts. Procurement organizations ought to diversify supplier relationships and incorporate contingency planning into contracts to minimize disruption from geopolitical or tariff-related shocks. Investment in workforce development-particularly in informatics, assay validation, and quality assurance-will be essential to realize the benefits of automation and digital quality tools. Collectively, these recommendations aim to align technical, operational, and commercial priorities to ensure accurate, reliable, and compliant diagnostic results across diverse testing environments.

A rigorous mixed-methods approach combining interviews standards analysis and triangulated evidence to ensure practical and technical relevance in quality control insights

The research methodology combines primary qualitative inputs, secondary literature review, and a structured synthesis of technical and regulatory sources to produce a comprehensive assessment of quality control dynamics. Primary inputs include interviews with laboratory directors, quality managers, and product leaders to capture operational pain points, validation practices, and procurement considerations, supplemented by consultations with regulatory experts to interpret guidance and enforcement trends. Secondary sources comprise peer-reviewed literature, standards documentation, and publicly available regulatory communications that inform the technical underpinnings of control design and validation.

Analytical methods integrate thematic coding of interview data, cross-validation with documented standards, and comparative case analysis to surface patterns in supplier approaches, laboratory workflows, and regional adoption. Care has been taken to triangulate findings across multiple evidence streams, ensuring that conclusions reflect both practical experience and documented requirements. Limitations are acknowledged where proprietary data or nascent technologies constrain full visibility, and recommendations emphasize adaptive strategies that can be refined as new evidence emerges. Overall, the methodology aims to balance technical rigor with practical relevance for stakeholders involved in diagnostics quality control.

Summarizing why interoperability workforce investment and supply chain transparency will determine future reliability and compliance in diagnostics quality control

In conclusion, maintaining and advancing quality control practices in in-vitro diagnostics is a strategic imperative that underpins clinical confidence and regulatory compliance. The sector is experiencing rapid change driven by technological innovation, greater reliance on molecular and immunoassay modalities, and heightened expectations for data traceability and supply chain transparency. These forces are creating both challenges and opportunities: challenges in harmonizing cross-platform performance and securing resilient supply lines, and opportunities in leveraging digital tools, modular control products, and collaborative partnerships to streamline validation and monitoring.

Moving forward, stakeholders who embrace interoperability, invest in workforce capability, and adopt proactive supply chain and validation strategies will be best positioned to ensure consistent diagnostic performance and respond effectively to evolving regulatory requirements. The synthesis presented here offers a framework for prioritizing actions and aligning resources so that laboratories and manufacturers can deliver reliable, patient-centered diagnostic outcomes in a complex and rapidly evolving environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of AI-driven image analysis for automated quality control in hematology testing
  • 5.2. Implementation of blockchain enabled traceability for reagent lot management in diagnostics
  • 5.3. Development of point-of-care molecular assays with integrated on device quality control metrics
  • 5.4. Regulatory harmonization of quality standards for rapid antigen tests across emerging markets
  • 5.5. Use of digital twin simulations for predicting system failures in automated immunoassay platforms
  • 5.6. Standardization of multi analyte proficiency testing protocols in centralized clinical laboratories
  • 5.7. Integration of IoT sensors for real time monitoring of pre analytic sample handling conditions
  • 5.8. Advancements in lyophilized control materials for extended stability in remote diagnostic settings

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In-Vitro Diagnostics Quality Control Market, by Product Type

  • 8.1. Analyzers & Instruments
    • 8.1.1. Automated Systems
    • 8.1.2. Semi-Automated Systems
  • 8.2. Control Materials
  • 8.3. QC Reagents
    • 8.3.1. Liquid Controls
    • 8.3.2. Lyophilized Controls
  • 8.4. Software Solutions
    • 8.4.1. Data Management Systems
    • 8.4.2. LIMS
    • 8.4.3. QC Software

9. In-Vitro Diagnostics Quality Control Market, by Technology

  • 9.1. Clinical Chemistry
    • 9.1.1. Colorimetric
    • 9.1.2. Turbidimetric
  • 9.2. Hematology
    • 9.2.1. Automated Cell Counters
    • 9.2.2. Flow Cytometry
  • 9.3. Immunoassay
    • 9.3.1. Chemiluminescence Immunoassay
    • 9.3.2. ELISA
    • 9.3.3. Fluorescence Immunoassay
  • 9.4. Microbiology
    • 9.4.1. Culture
    • 9.4.2. PCR
  • 9.5. Molecular Diagnostics
    • 9.5.1. Next-Generation Sequencing
    • 9.5.2. PCR

10. In-Vitro Diagnostics Quality Control Market, by Application

  • 10.1. Cardiology
    • 10.1.1. Cardiac Marker Testing
    • 10.1.2. Point-Of-Care Testing
  • 10.2. Genetic Testing
    • 10.2.1. Carrier Screening
    • 10.2.2. Prenatal Testing
  • 10.3. Infectious Disease Testing
    • 10.3.1. Bacterial Detection
    • 10.3.2. Viral Detection
  • 10.4. Oncology
    • 10.4.1. Minimal Residual Disease
    • 10.4.2. Tumor Marker Testing
  • 10.5. Toxicology
    • 10.5.1. Drugs Of Abuse
    • 10.5.2. Therapeutic Drug Monitoring

11. In-Vitro Diagnostics Quality Control Market, by End User

  • 11.1. Blood Banks
    • 11.1.1. National Blood Banks
    • 11.1.2. Regional Blood Banks
  • 11.2. Diagnostic Laboratories
    • 11.2.1. Hospital-Based Laboratories
    • 11.2.2. Independent Laboratories
  • 11.3. Hospitals & Clinics
    • 11.3.1. Clinic Laboratories
    • 11.3.2. Reference Laboratories
  • 11.4. Research Institutes
    • 11.4.1. Academic Institutes
    • 11.4.2. Private Research Laboratories

12. In-Vitro Diagnostics Quality Control Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. In-Vitro Diagnostics Quality Control Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. In-Vitro Diagnostics Quality Control Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Bio-Rad Laboratories, Inc.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Abbott Laboratories
    • 15.3.4. Roche Diagnostics International AG
    • 15.3.5. Danaher Corporation
    • 15.3.6. Sysmex Corporation
    • 15.3.7. Siemens Healthineers AG
    • 15.3.8. Ortho Clinical Diagnostics, Inc.
    • 15.3.9. Randox Laboratories Ltd
    • 15.3.10. BioMerieux S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ANALYZERS & INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CONTROL MATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CONTROL MATERIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CONTROL MATERIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CONTROL MATERIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CONTROL MATERIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CONTROL MATERIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIQUID CONTROLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIQUID CONTROLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIQUID CONTROLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIQUID CONTROLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIQUID CONTROLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIQUID CONTROLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LYOPHILIZED CONTROLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LYOPHILIZED CONTROLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LYOPHILIZED CONTROLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LYOPHILIZED CONTROLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LYOPHILIZED CONTROLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LYOPHILIZED CONTROLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY LIMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY QC SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COLORIMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TURBIDIMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TURBIDIMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TURBIDIMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TURBIDIMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TURBIDIMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TURBIDIMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIAC MARKER TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIAC MARKER TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIAC MARKER TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIAC MARKER TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIAC MARKER TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARDIAC MARKER TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BACTERIAL DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BACTERIAL DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BACTERIAL DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BACTERIAL DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BACTERIAL DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY BACTERIAL DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY VIRAL DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY VIRAL DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY VIRAL DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY VIRAL DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY VIRAL DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY VIRAL DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TUMOR MARKER TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TUMOR MARKER TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TUMOR MARKER TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TUMOR MARKER TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TUMOR MARKER TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TUMOR MARKER TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL IN-VITRO DIAGNOSTICS QUALITY CONTROL MARKET SIZE, BY TOXICOLOGY,